Conexeu Sciences Expected to Begin Trading on Nasdaq on May 21
Conexeu Sciences, a preclinical developer of a regenerative tissue device for wound care and aesthetics, filed a resale prospectus with the SEC stating that it expects its common stock to begin trading on the Nasdaq on or about Thursday, May 21, in connection with its direct listing. The company registered 9.5M shares that may be sold by the Registered Securityholders identified in the prospectus. Conexeu Sciences will not raise new capital in its listing. The stock opened for trading earlier at a price of $13.50 per share.
